# Twice-Monthly GLP-1 Shot Offers New Option for Blood Sugar and Weight Management
A new trial shows that a twice-monthly GLP-1 injection helps people manage blood sugar levels and lose weight more effectively than weekly doses. Researchers tested this longer-acting formulation and found it delivered comparable results to traditional weekly injections while requiring fewer shots per month.
GLP-1 drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) work by slowing digestion and signaling fullness to the brain. They've become popular for both diabetes management and weight loss. The challenge for many patients centers on injection frequency and needle anxiety.
This trial examined whether spacing doses further apart maintained the same benefits. Patients receiving the twice-monthly shot experienced similar improvements in blood sugar control and weight loss compared to those on weekly schedules. The less frequent dosing schedule could reduce treatment burden and help people stick with their medications long-term, a problem doctors call adherence.
The implications for families managing type 2 diabetes are straightforward. Fewer injections means less frequent pharmacy visits and reduced needle-related stress, particularly for children and teens. Parents juggling medication schedules appreciate simpler routines.
However, families considering GLP-1 treatment should discuss timing with their doctor. These medications aren't appropriate for everyone. People with personal or family histories of thyroid cancer, multiple endocrine neoplasia syndrome, or certain diabetic eye conditions need to avoid them. Pregnant women and those planning pregnancy should also skip these drugs.
Cost remains a barrier. Insurance coverage varies widely, and out-of-pocket expenses can reach hundreds of dollars monthly. Families should contact their insurance company before starting treatment.
Side effects include nausea, constipation, and vomiting, typically mild